Perseus SENOLYTIX
1 employees on LinkedIn · 1 known investors
Perseus SENOLYTIX is an oncology company developing MitoXcel oncopeptides, sequence-engineered peptides that target cancer cells through mitochondrial membrane potential rather than receptor- or kinase-based mechanisms. It pursues first-in-class treatments for hematologic and solid tumors, with preclinical activity shown in leukemia, lymphoma, melanoma, and breast cancer models.</parameter> <parameter name="hq_city">Houston
Investors · 1
Frequently asked questions
- What does Perseus SENOLYTIX do?
- Perseus SENOLYTIX is an oncology company developing MitoXcel oncopeptides, sequence-engineered peptides that target cancer cells through mitochondrial membrane potential rather than receptor- or kinase-based mechanisms. It pursues first-in-class treatments for hematologic and solid tumors, with preclinical activity shown in leukemia, lymphoma, melanoma, and breast cancer models.</parameter> <parameter name="hq_city">Houston
- Who are Perseus SENOLYTIX's investors?
- Perseus SENOLYTIX's investors include Rapha Capital Management, LLC.